再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

REGN 再生元制药公司

休市中 09-19 16:00:00 EDT

591.99

-6.72

-1.12%

盘后591.99

+0.000.00%

19:56 EDT

最高603.47	最低591.00	成交量217.80万
今开602.54	昨收598.71	日振幅2.08%
总市值627.44亿	流通市值611.54亿	总股本1.06亿
成交额12.94亿	换手率2.11%	流通股本1.03亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"再生元制药公司","latestPrice":591.99,"timestamp":1758312000000,"preClose":598.71,"halted":0,"volume":2177999,"hourTrading":{"tag":"盘后","latestPrice":591.99,"preClose":591.99,"latestTime":"19:56 EDT","volume":402039,"amount":238004112.6713,"timestamp":1758326190590},"delay":0,"floatShares":103302739,"shares":105987442,"eps":39.673737,"marketStatus":"休市中","change":-6.72,"latestTime":"09-19 16:00:00 EDT","open":602.54,"high":603.465,"low":591,"amount":1294268936.1532,"amplitude":0.02082,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":39.673737,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1758528000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":598.71,"dividendRate":0.00446,"preHourTrading":{"tag":"盘前","latestPrice":600.29,"preClose":598.71,"latestTime":"09:29 EDT","volume":884,"amount":531063.3536,"timestamp":1758288599999},"postHourTrading":{"tag":"盘后","latestPrice":591.99,"preClose":591.99,"latestTime":"19:56 EDT","volume":402039,"amount":238004112.6713,"timestamp":1758326190590},"volumeRatio":2.4222608968734107,"impliedVol":0.3302,"impliedVolPercentile":0.156},"requestUrl":"/m/hq/s/REGN/tweets","defaultTab":"tweets","newsList":[{"id":"1159145432","title":"Courage二期临床试验结果在EASD会议上发布，显示通过保持肌肉质量有望改善GLP-1受体激动剂减重效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1159145432","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159145432?lang=zh_cn&edition=full","pubTime":"2025-09-17 21:30","pubTimestamp":1758115818,"startTime":"0","endTime":"0","summary":"Courage二期临床试验结果在EASD会议上发布，显示通过保持肌肉质量有望改善GLP-1受体激动剂减重效果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0889565916.HKD","LU2237438978.USD","LU2362541513.USD","LU0823416689.USD","BK4139","LU1917777945.USD","LU0882574055.USD","LU2468319806.SGD","LU2362540622.SGD","LU2106854487.HKD","LU1974910355.USD","LU0114720955.EUR","LU2023250504.SGD","LU0109394709.USD","BK4585","LU0058720904.USD","LU0823434583.USD","BK4588","REGN","LU0320765992.SGD","LU0823434740.USD","LU2089984988.USD","LU0053666078.USD","LU2362541273.HKD"],"gpt_icon":0},{"id":"2568033410","title":"再生元制药的骨病疗法达到后期试验的主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2568033410","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568033410?lang=zh_cn&edition=full","pubTime":"2025-09-17 21:17","pubTimestamp":1758115074,"startTime":"0","endTime":"0","summary":"格隆汇9月17日｜再生元制药表示，对一种影响骨组织的罕见遗传性疾病的实验性治疗达到了后期试验的主要目标。该公司称，其药物garetosmab在减少渐进性纤维性骨质增生症患者的异常骨骼生长方面疗效显著。该公司计划在2025年底前提交该药在美国的上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250917211817a7266d04&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2362540622.SGD","LU0823416689.USD","LU2089984988.USD","BK4588","LU0320765992.SGD","BK4139","LU1917777945.USD","LU2468319806.SGD","LU1974910355.USD","LU2362541513.USD","LU0823434583.USD","LU2106854487.HKD","LU0823434740.USD","LU2362541273.HKD","REGN","BK4585","LU0289739699.SGD","LU0889565916.HKD","LU2237438978.USD","LU0053666078.USD","LU2023250504.SGD","LU0882574055.USD","LU0114720955.EUR","LU0058720904.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"1141868372","title":"Regeneron公布超罕见遗传性疾病进行性肌肉骨化症成人患者三期临床试验积极结果，显示Garetosmab可预防超过99%的异常骨化","url":"https://stock-news.laohu8.com/highlight/detail?id=1141868372","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141868372?lang=zh_cn&edition=full","pubTime":"2025-09-17 19:01","pubTimestamp":1758106915,"startTime":"0","endTime":"0","summary":"Regeneron公布超罕见遗传性疾病进行性肌肉骨化症成人患者三期临床试验积极结果，显示Garetosmab可预防超过99%的异常骨化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","LU0882574055.USD","BK4588","LU2362541513.USD","LU2362540622.SGD","BK4585","LU0058720904.USD","LU0289739699.SGD","REGN","LU0320765992.SGD","LU0889565916.HKD","LU2023250504.SGD","LU1974910355.USD","LU0823416689.USD","LU0053666078.USD","LU0823434740.USD","LU0109394709.USD","LU2106854487.HKD","LU2237438978.USD","BK4139","LU0114720955.EUR","LU1917777945.USD","LU2089984988.USD","LU2362541273.HKD","LU0823434583.USD"],"gpt_icon":0},{"id":"1126254613","title":"Libtayo®（cemiplimab）联合化疗五年数据显示，晚期非小细胞肺癌患者生存获益显著且持久","url":"https://stock-news.laohu8.com/highlight/detail?id=1126254613","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126254613?lang=zh_cn&edition=full","pubTime":"2025-09-09 19:01","pubTimestamp":1757415700,"startTime":"0","endTime":"0","summary":"Libtayo®（cemiplimab）联合化疗的五年临床数据进一步证实，该治疗方案为晚期非小细胞肺癌患者带来了显著且持久的生存获益改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237438978.USD","LU2362541513.USD","LU0058720904.USD","BK4139","LU0823434740.USD","LU2106854487.HKD","LU2362540622.SGD","LU2362541273.HKD","LU2468319806.SGD","BK4588","LU0053666078.USD","LU0114720955.EUR","LU0823434583.USD","LU0289739699.SGD","LU2089984988.USD","LU0320765992.SGD","LU2023250504.SGD","LU1917777945.USD","LU0882574055.USD","LU1974910355.USD","LU0889565916.HKD","REGN","LU0109394709.USD","LU0823416689.USD","BK4585"],"gpt_icon":0},{"id":"1137904881","title":"再生元制药公司计划2026年上半年启动额外三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1137904881","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137904881?lang=zh_cn&edition=full","pubTime":"2025-09-08 18:32","pubTimestamp":1757327568,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，计划在2026年上半年开始进行额外的三期临床试验开发项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU2089984988.USD","LU2362540622.SGD","LU2362541273.HKD","LU0058720904.USD","BK4139","LU1974910355.USD","BK4588","LU2362541513.USD","LU2468319806.SGD","LU2237438978.USD","LU0823434583.USD","LU0889565916.HKD","LU0053666078.USD","LU0320765992.SGD","LU1917777945.USD","LU0109394709.USD","LU0289739699.SGD","LU0882574055.USD","LU2106854487.HKD","LU0823434740.USD","REGN","LU0823416689.USD","BK4585","LU2023250504.SGD"],"gpt_icon":0},{"id":"1195158130","title":"再生元制药公司推进过敏治疗管线发展，两项3期临床试验证实首创猫过敏和桦树过敏抗体阻断剂疗效显著","url":"https://stock-news.laohu8.com/highlight/detail?id=1195158130","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195158130?lang=zh_cn&edition=full","pubTime":"2025-09-08 18:30","pubTimestamp":1757327423,"startTime":"0","endTime":"0","summary":"再生元制药公司在过敏治疗领域取得重要进展，该公司两项3期临床试验均获得积极结果，这些试验正在评估针对猫过敏和桦树过敏的首创抗体阻断剂的疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0114720955.EUR","LU1917777945.USD","LU2237438978.USD","LU0889565916.HKD","LU0289739699.SGD","LU2362541513.USD","LU0882574055.USD","LU2362540622.SGD","LU0053666078.USD","LU0109394709.USD","BK4139","LU2089984988.USD","LU0823434740.USD","BK4588","LU2468319806.SGD","LU1974910355.USD","LU2023250504.SGD","LU0058720904.USD","LU0823416689.USD","REGN","LU0823434583.USD","LU2362541273.HKD","LU0320765992.SGD","LU2106854487.HKD"],"gpt_icon":0},{"id":"2564803087","title":"DBS Bank Adjusts Price Target on Regeneron Pharmaceuticals to $720 From $760, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2564803087","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564803087?lang=zh_cn&edition=full","pubTime":"2025-09-02 18:13","pubTimestamp":1756808028,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $730.36, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"星展银行将再生元制药目标价从760美元调整至720美元，维持买入评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RJAW.SI","REGN","DBS"],"gpt_icon":0},{"id":"2562711596","title":"Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $831 From $813, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2562711596","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562711596?lang=zh_cn&edition=full","pubTime":"2025-08-27 17:37","pubTimestamp":1756287428,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $730.36, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"杰富瑞将再生元制药目标价从813美元调整至831美元，维持买入评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN"],"gpt_icon":0},{"id":"1139753418","title":"再生元制药公司：Cemdisiran治疗组在第24周内未因不良事件导致治疗中止","url":"https://stock-news.laohu8.com/highlight/detail?id=1139753418","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139753418?lang=zh_cn&edition=full","pubTime":"2025-08-26 19:03","pubTimestamp":1756206213,"startTime":"0","endTime":"0","summary":"再生元制药公司：Cemdisiran治疗组在第24周内未因不良事件导致治疗中止","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1974910355.USD","LU2237438978.USD","LU2362541273.HKD","LU2023250504.SGD","LU0320765992.SGD","LU0289739699.SGD","LU0882574055.USD","LU0889565916.HKD","LU2468319806.SGD","LU0823434740.USD","LU0058720904.USD","BK4585","REGN","LU0114720955.EUR","BK4139","LU2089984988.USD","BK4588","LU0823434583.USD","LU0053666078.USD","LU0109394709.USD","LU1917777945.USD","LU0823416689.USD","LU2362540622.SGD","LU2106854487.HKD","LU2362541513.USD"],"gpt_icon":0},{"id":"1161701990","title":"再生元制药公司：Cemdisiran单药疗法每三个月皮下给药一次，达到主要和关键次要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1161701990","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161701990?lang=zh_cn&edition=full","pubTime":"2025-08-26 19:01","pubTimestamp":1756206085,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，其Cemdisiran单药疗法采用每三个月皮下给药一次的给药方案，在临床试验中成功达到了主要终点和关键次要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU0823434740.USD","REGN","LU2023250504.SGD","LU0053666078.USD","LU0823434583.USD","LU2362541273.HKD","LU0114720955.EUR","LU0320765992.SGD","LU2237438978.USD","LU2362540622.SGD","LU1917777945.USD","LU0889565916.HKD","LU0058720904.USD","LU1974910355.USD","BK4588","BK4139","LU0882574055.USD","LU2106854487.HKD","LU2362541513.USD","LU2089984988.USD","LU0109394709.USD","BK4585","LU2468319806.SGD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2558507836","title":"Truist Securities Adjusts Regeneron Pharmaceuticals Price Target to $812 From $940, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2558507836","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558507836?lang=zh_cn&edition=full","pubTime":"2025-08-11 20:20","pubTimestamp":1754914838,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $720.57, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resea","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"Truist Securities将再生元制药目标价从940美元调整至812美元，维持买入评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN"],"gpt_icon":0},{"id":"2557154834","title":"再生元制药公司8月7日成交额为4.54亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557154834","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557154834?lang=zh_cn&edition=full","pubTime":"2025-08-08 13:41","pubTimestamp":1754631697,"startTime":"0","endTime":"0","summary":"美东时间2025年8月7日，再生元制药公司成交额为4.54亿美元，成交额较昨日减少5.81%，当日成交量为81.13万股。再生元制药公司于2025年8月7日涨0.84%，报559.8美元，该股过去5个交易日涨2.63%，年初至今跌21.19%，过去60日跌2.6%。该公司有多种已上市产品，包括获批用于湿性年龄相关性黄斑变性和其他眼病的低剂量Eylea 和 Eylea HD、免疫学领域的达必妥；用于降低低密度脂蛋白胆固醇的波立达；肿瘤学领域的Libtayo；以及类风湿性关节炎领域的Kevzara。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808134147a6da4861&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0053666078.USD","LU0109394709.USD","REGN","LU2468319806.SGD","LU2362541273.HKD","LU1974910355.USD","LU2362540622.SGD","LU1917777945.USD","LU0289739699.SGD","BK4588","LU0882574055.USD","LU0320765992.SGD","LU0823416689.USD","BK4139","LU2362541513.USD","LU2089984988.USD","LU2106854487.HKD","LU0823434740.USD","LU0114720955.EUR","BK4585","LU2023250504.SGD","LU2237438978.USD","LU0058720904.USD","LU0889565916.HKD","LU0823434583.USD"],"gpt_icon":0},{"id":"2557536345","title":"再生元制药公司8月6日成交额为4.82亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557536345","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557536345?lang=zh_cn&edition=full","pubTime":"2025-08-07 13:35","pubTimestamp":1754544950,"startTime":"0","endTime":"0","summary":"美东时间2025年8月6日，再生元制药公司成交额为4.82亿美元，成交额较昨日减少15.09%，当日成交量为86.52万股。再生元制药公司于2025年8月6日跌2.59%，报555.13美元，该股过去5个交易日涨0.1%，年初至今跌21.85%，过去60日涨5.34%。该公司有多种已上市产品，包括获批用于湿性年龄相关性黄斑变性和其他眼病的低剂量Eylea 和 Eylea HD、免疫学领域的达必妥；用于降低低密度脂蛋白胆固醇的波立达；肿瘤学领域的Libtayo；以及类风湿性关节炎领域的Kevzara。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807133601a6d80559&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0053666078.USD","LU0823434740.USD","LU0289739699.SGD","BK4585","LU0889565916.HKD","LU1917777945.USD","LU0320765992.SGD","LU2362541513.USD","BK4588","LU0823416689.USD","LU2106854487.HKD","LU2468319806.SGD","LU2237438978.USD","LU0058720904.USD","LU0109394709.USD","LU2089984988.USD","LU0882574055.USD","LU2362540622.SGD","LU1974910355.USD","LU2023250504.SGD","LU2362541273.HKD","LU0114720955.EUR","REGN","BK4139","LU0823434583.USD"],"gpt_icon":0},{"id":"2557340369","title":"再生元制药公司8月5日成交额为5.67亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557340369","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557340369?lang=zh_cn&edition=full","pubTime":"2025-08-06 13:29","pubTimestamp":1754458165,"startTime":"0","endTime":"0","summary":"美东时间2025年8月5日，再生元制药公司成交额为5.67亿美元，成交额较昨日减少26.98%，当日成交量为99.35万股。再生元制药公司于2025年8月5日跌0.29%，报569.9美元，该股过去5个交易日涨2.11%，年初至今跌19.77%，过去60日涨4.22%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-05|5.67亿|-26.98%|99.35万|#|2025-08-04|7.77亿|-15.76%|136.27万|#|2025-08-01|9.22亿|19.03%|165.68万|#|2025-07-31|7.75亿|146.52%|141.38万|#|2025-07-30|3.14亿|-30.83%|56.49万|Regeneron Pharmaceuticals 发现、开发和商业化用于治疗眼部疾病、心血管疾病、癌症和炎症的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806132928a477f956&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0882574055.USD","LU2023250504.SGD","LU0823434740.USD","LU2237438978.USD","LU0320765992.SGD","LU0053666078.USD","LU2362540622.SGD","LU1974910355.USD","LU0889565916.HKD","LU1917777945.USD","LU2468319806.SGD","LU0823434583.USD","BK4585","LU2362541513.USD","LU0109394709.USD","BK4139","LU0823416689.USD","BK4588","LU0114720955.EUR","LU0058720904.USD","LU2362541273.HKD","LU0289739699.SGD","REGN","LU2106854487.HKD","LU2089984988.USD"],"gpt_icon":0},{"id":"2557352067","title":"再生元制药公司8月4日成交额为7.77亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557352067","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557352067?lang=zh_cn&edition=full","pubTime":"2025-08-05 13:29","pubTimestamp":1754371759,"startTime":"0","endTime":"0","summary":"美东时间2025年8月4日，再生元制药公司成交额为7.77亿美元，成交额较昨日减少15.76%，当日成交量为136.27万股。再生元制药公司于2025年8月4日涨2.27%，报571.54美元，该股过去5个交易日涨2.31%，年初至今跌19.54%，过去60日涨2.04%。该公司有多种已上市产品，包括获批用于湿性年龄相关性黄斑变性和其他眼病的低剂量Eylea 和 Eylea HD、免疫学领域的达必妥；用于降低低密度脂蛋白胆固醇的波立达；肿瘤学领域的Libtayo；以及类风湿性关节炎领域的Kevzara。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805132930a475d91d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2089984988.USD","BK4139","REGN","LU0058720904.USD","LU0320765992.SGD","LU2106854487.HKD","LU0053666078.USD","LU0823434583.USD","LU2023250504.SGD","LU2237438978.USD","LU0109394709.USD","LU0882574055.USD","LU2468319806.SGD","LU0114720955.EUR","LU2362540622.SGD","LU1917777945.USD","LU0823416689.USD","LU1974910355.USD","LU0823434740.USD","LU2362541273.HKD","LU2362541513.USD","LU0289739699.SGD","BK4585","BK4588","LU0889565916.HKD"],"gpt_icon":0},{"id":"2556118385","title":"RBC Raises Price Target on Regeneron Pharmaceuticals to $695 From $688, Keeps Sector Perform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2556118385","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556118385?lang=zh_cn&edition=full","pubTime":"2025-08-04 19:17","pubTimestamp":1754306249,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $726.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resea","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"加拿大皇家银行将再生元制药目标价从688美元上调至695美元，维持行业表现评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN"],"gpt_icon":0},{"id":"2556474918","title":"美股财报 | 再生元制药发布Q2财报 前半年累计净利润同比增长2.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556474918","media":"同花顺iNews","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556474918?lang=zh_cn&edition=full","pubTime":"2025-08-02 12:00","pubTimestamp":1754107210,"startTime":"0","endTime":"0","summary":"再生元制药发布Q2财报，2025财年前六月累计收入67.04亿美元，去年同期累计收入为66.92亿美元，同比增长0.18%。2025财年前六月累计净利润22.00亿美元，去年同期累计净利润为21.54亿美元，同比增长2.14%。再生元制药公司于1988年在纽约州成立。再生元制药公司是一家完全集成的生物技术公司，它发现、发明、开发、制造和商业化治疗严重疾病的药物。其目标是继续成为一家综合性、多产品的生物技术公司，为患者和医疗专业人员提供预防和治疗人类疾病的重要选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250802120522a470c879&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REGN"],"gpt_icon":0},{"id":"1153428085","title":"异动解读 | 再生元制药公司财报超预期，股价盘中大涨6.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153428085","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153428085?lang=zh_cn&edition=full","pubTime":"2025-08-01 21:43","pubTimestamp":1754055798,"startTime":"0","endTime":"0","summary":"再生元制药公司今日盘中大涨6.88%，引发市场广泛关注。这一显著涨幅主要源于公司发布的2025年第二季度财报远超市场预期。根据再生元制药公司公布的财报，2025年第二季度收入同比增长4%至36.8亿美元，超过分析师预期的32.84亿美元。除财务业绩外，再生元制药公司还公布了多项积极的业务进展。这些因素共同推动了投资者信心，导致股价大幅上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["REGN"],"gpt_icon":0},{"id":"2556381930","title":"Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines","url":"https://stock-news.laohu8.com/highlight/detail?id=2556381930","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556381930?lang=zh_cn&edition=full","pubTime":"2025-08-01 21:22","pubTimestamp":1754054566,"startTime":"0","endTime":"0","summary":"Regeneron Q2 revenue rose 4% to $3.68 billion, driven by Dupixent and antibody profits, while FDA delays impacted Eylea HD and odronextamab approvals.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Regeneron的管道受到Catalent延误的打击，但Dupixent大放异彩","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/25/08/46792668/regenerons-pipeline-hit-by-catalent-delays-but-dupixent-shines","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1551013425.SGD","IE00BFXG1179.USD","LU1093756168.USD","SG9999001440.SGD","BK4121","BK4139","REGN","LU0820561909.HKD","HD","BK4566","BK4599","LU0320765992.SGD","LU1069344957.HKD","LU1162221912.USD","LU0820561818.USD","LU0823434583.USD","LU2023250504.SGD","LU0823411888.USD","CRL","LU2468319806.SGD","BK4567","LU0114720955.EUR","CTLT","IE00B1XK9C88.USD","BK4534","LU1917777945.USD","BK4530","BK4550","SNY","LU1974910355.USD","IE00BSNM7G36.USD","LU0820562030.AUD","LU0757428866.USD","BK4581","LU1778281490.HKD","BK4007","LU2362541273.HKD","IE00BZ1G4Q59.USD","LU0289739699.SGD","LU1496350502.SGD","LU0234572021.USD","LU1929549753.HKD","LU0154236417.USD","LU1496350171.SGD","IE00BWXC8680.SGD","LU1674673691.USD","LU1914381329.SGD","LU0889565916.HKD","LU2756315664.SGD"],"gpt_icon":1},{"id":"2556814123","title":"Sector Update: Health Care Stocks Mixed Premarket Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2556814123","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556814123?lang=zh_cn&edition=full","pubTime":"2025-08-01 21:21","pubTimestamp":1754054519,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed premarket Friday, with The Health Care Select Sector SPDR Fund  up 0.1% and the iShares Biotechnology ETF  0.5% lower.Moderna  shares were more than 7% lower after the company reported a decline in Q2 revenue and cut the higher end of its 2025 revenue outlook.Regeneron Pharmaceuticals  stock was up nearly 6% after the company posted higher Q2 adjusted earnings and revenue.Avantor  shares were down more than 11% after the company posted lower Q2 adjusted earnings and net sales.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"行业更新：周五盘前医疗保健股涨跌互现","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2362540622.SGD","LU0823416689.USD","LU2089984988.USD","BK4588","LU0320765992.SGD","XLV","BK4139","BK4581","LU1917777945.USD","BK4548","LU1974910355.USD","LU2362541513.USD","LU2468319806.SGD","IBB","LU0823434583.USD","LU2106854487.HKD","LU0823434740.USD","BK4533","BK4568","LU2362541273.HKD","BK4534","REGN","MRNA","BK4121","BK4585","LU0289739699.SGD","LU0889565916.HKD","BK4551","LU2237438978.USD","LU0053666078.USD","AVTR","BK4501","LU2023250504.SGD","LU0882574055.USD","BK4532","LU0114720955.EUR","LU0058720904.USD","LU0109394709.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":0.0571},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.1614},{"period":"6month","weight":-0.101},{"period":"1year","weight":-0.4853},{"period":"ytd","weight":-0.1689}],"compareEarnings":[{"period":"1week","weight":0.0096},{"period":"1month","weight":0.0401},{"period":"3month","weight":0.1168},{"period":"6month","weight":0.1768},{"period":"1year","weight":0.1624},{"period":"ytd","weight":0.1324}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再生元制药公司于1988年在纽约州成立。再生元制药公司是一家完全集成的生物技术公司，它发现、发明、开发、制造和商业化治疗严重疾病的药物。其正在开发的商业化药物和候选产品旨在帮助患有眼疾、过敏性和炎症性疾病、癌症、心血管和代谢性疾病、疼痛、传染病和罕见疾病的患者。它的核心业务战略是在基础科学研究和发现启用技术方面保持坚实的基础，并建立在临床开发、制造和商业能力的基础上。其目标是继续成为一家综合性、多产品的生物技术公司，为患者和医疗专业人员提供预防和治疗人类疾病的重要选择。","yearOnYearQuotes":[{"month":1,"riseRate":0.529412,"avgChangeRate":0.03899},{"month":2,"riseRate":0.411765,"avgChangeRate":0.087815},{"month":3,"riseRate":0.470588,"avgChangeRate":-0.044318},{"month":4,"riseRate":0.470588,"avgChangeRate":0.017191},{"month":5,"riseRate":0.628571,"avgChangeRate":0.057479},{"month":6,"riseRate":0.428571,"avgChangeRate":0.006745},{"month":7,"riseRate":0.657143,"avgChangeRate":0.052646},{"month":8,"riseRate":0.542857,"avgChangeRate":0.022877},{"month":9,"riseRate":0.485714,"avgChangeRate":0.024744},{"month":10,"riseRate":0.382353,"avgChangeRate":-0.006135},{"month":11,"riseRate":0.529412,"avgChangeRate":0.041578},{"month":12,"riseRate":0.5,"avgChangeRate":0.045405}],"exchange":"NASDAQ","name":"再生元制药公司","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.3","shortVersion":"4.35.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再生元制药公司,REGN,再生元制药公司股票,再生元制药公司股票老虎,再生元制药公司股票老虎国际,再生元制药公司行情,再生元制药公司股票行情,再生元制药公司股价,再生元制药公司股市,再生元制药公司股票价格,再生元制药公司股票交易,再生元制药公司股票购买,再生元制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}